Sustained product growth and margin improvement. July–September 2013 (third quarter) License revenue amounted to SKr 114 million (Q3 '12: SKr 109 million), an increase of 8 percent currency adjusted. Maintenance revenue was SKr 227 million (Q3 '12: SKr 224 million), an improvement of 4 percent currency adjusted. Consulting revenue amounted to SKr 291 million (Q3 '12: SKr 268 million), an increase of 11 percent currency adjusted. Net revenue was SKr 633 million (Q3 '12: SKr 612 million), an improvement of 6 percent currency adjusted. EBIT amounted to SKr 66 million (Q3 '12: SKr 29 million). Cash flow after investments was SKr -43 million (Q3 '12: SKr -28 million). Earnings per share after full dilution amounted to SKr 1.94 (Q3 '12: SKr 0.86). January–September 2013 (nine months) License revenue amounted to SKr 326 million (YTD '12: SKr 284 million), an increase of 20 percent currency adjusted. Maintenance revenue was SKr 685 million (YTD '12: SKr 678 million), an improvement of 5 percent currency adjusted. Consulting revenue amounted to SKr 935 million (YTD '12: SKr 930 million), an increase of 4 percent currency adjusted. Net revenue was SKr 1,950 million (YTD '12: SKr 1,907 million), an improvement of 6 percent currency adjusted. EBIT amounted to SKr 40 million (YTD '12: SKr 69 million), including one-off costs for efficiency program. Cash flow after investments was SKr 37 million (YTD '12: SKr -96 million). Earnings per share after full dilution amounted to SKr 0.71 (YTD '12: SKr 1.71). Outlook For 2013, IFS expects strong license revenue growth and an improvement in EBIT. Legal dispute The counterparty has increased its claim in the legal dispute that IFS is involved in, concerning the partly-owned company IFS Sri Lanka. IFS’s position with respect to the dispute remains unchanged: IFS rejects the counterparty’s claims as being frivolous and completely unmeritorious and unfounded, and rejects the claims in their entirety. Contact Information Mark Boulton Telefon: 44 1494 428900 Chief Marketing Officer press@ifsworld.com (mark.boulton@ifsworld.com) Frédéric Guigues Telefon: 46 8 58 78 45 00 Investor Relations frederic.guigues@ifsworld.com About IFS IFS (http://www.ifsworld.com/en/about-ifs/)™is a public company (XSTO: IFS) founded in 1983 that develops (http://www.ifsworld.com/en/solutions/architecture -and-technology/), supplies, and implements (http://www.ifsworld.com/en/services/) IFS Applications (http://www.ifsworld.com/en/solutions/ifs-applications-8/)™, a component-based extended ERP suite. IFS focuses on industries (http://www.ifsworld.com/en/industries/) where management of any of the following four core processes is strategic: service (http://www.ifsworld.com/en/solutions/field-service-management -software/) & asset (http://www.ifsworld.com/en/solutions/enterprise-asset -management-software/), manufacturing (http://www.ifsworld.com/en/solutions/manufacturing/), supply chain (http://www.ifsworld.com/en/solutions/supply-chain/), and projects (http://www.ifsworld.com/en/solutions/projects/). The company has 2,100 customers (http://www.ifsworld.com/en/customers/) and is present in approximately 60 countries with 2,800 employees in total. Net revenue in 2012 was SKr 2.7 billion. More information on IFS is available at www.IFSWORLD.com Follow us on Twitter: @ifsworld (http://twitter.com/ifsworld) Visit the IFS Blogs on technology, innovation and creativity: http://blogs.ifsworld.com/ IFS discloses the information provided herein pursuant to the Financial Instruments Trading Act (1991:980) and/or the Securities Markets Act (2007:528). The information was submitted for publication on October 24, 2013 at 8:00 a.m. (CEST).
IFS Interim Report January–September 2013 Sustained
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Exploring the Future of Protein Drug Manufacturing Growth
The Rising Landscape of Protein Drugs As the healthcare industry evolves, protein drugs are making waves, fundamentally changing the approach pharmaceutical companies take to manage chronic and life-threatening conditions. With a surge in demand for precise biologic-based therapies, leading pharmaceutical firms have been diligently working on solutions that not only...
Continue Reading
Nexdata Launches Advanced AI Data Collection Facility
Nexdata Revolutionizes AI Data with New Operational Facility As the world of artificial intelligence advances rapidly, the emergence of embodied AI marks a shift toward more tangible and capable intelligent systems. However, within this evolving landscape, there is a critical challenge: the shortage of high-quality, real-world interaction data. Nexdata, an outstanding...
Continue Reading
Starbucks Adopts New Pay Structure Amid Sales Challenges
Starbucks Corp. Restructures Pay System for Corporate Employees Starbucks Corp. (NASDAQ: SBUX) has announced a 2% salary increase for all North American corporate employees, shifting away from its previous merit-based pay increase system. This decision comes as part of the company’s initiative to manage operational costs and rejuvenate its business model during a period...
Continue Reading
Target Corporation Investors Encouraged to Pursue Class Action
Understanding Your Rights as an Investor in Target Corporation In recent developments, investors in Target Corporation (NYSE: TGT) are presented with a significant opportunity to engage in a class action lawsuit due to potential securities fraud. This situation arises from allegations that the company made misleading statements during a specific period of time. The Basics...
Continue Reading
Swig Launches Exciting Gold Tumbler Giveaway for 2026
Swig Kicks Off 2026 with a Unique Gold Tumbler Giveaway Swig is thrilled to announce an exhilarating opportunity for fans nationwide to engage in the "FREE SWIG FOR A YEAR 2026 – The Gold Tumbler Giveaway." This amazing campaign invites participants to win a one-of-a-kind Gold Tumbler, granting holders one free 44 oz. refill each day for an entire year, based on the...
Continue Reading